WHO Approves MVA-BN Vaccine to Prevent Monkeypox

The World Health Organization (WHO) has approved the MVA-BN vaccine, developed by Bavarian Nordic, a Danish biotechnology company, to prevent monkeypox. This approval marks a significant milestone in the fight against the disease, both in the context of the current epidemic in Africa and future outbreaks.

WHO Director-General Tedros Adhanom Ghebreyesus announced the approval, emphasizing the need to increase the supply and distribution of vaccines to ensure equitable access to the most vulnerable groups.

Key Facts About the MVA-BN Vaccine

• Developed by Bavarian Nordic, a Danish biotechnology company
• Approved by the World Health Organization (WHO) to prevent monkeypox
• First dose to be included in the list of vaccines approved under international standards

Importance of the Approval

The approval of the MVA-BN vaccine is a crucial step in the fight against monkeypox, particularly in Africa where the disease is currently epidemic. The vaccine’s approval under international standards ensures its safety and efficacy, paving the way for increased access to vulnerable populations.